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Summary
Objectives: To determine the analgesic effectiveness, the effect on physical function and the safety of opioids in patients with osteoarthritis
(OA).
Search strategy: A systematic literature search was performed in electronic databases up to October 2006. A hand search of references was
also performed.
Selection criteria: All randomized controlled trials evaluating the efﬁcacy and/or the safety of opioids vs placebo or non-opioid analgesics in
patients with OA were selected.
Data collection and analysis: Data were collected using a predetermined form. Statistical analysis determined in each trial the effect size to
assess the magnitude of treatment effect and the number needed to harm (NNH) to evaluate opioids safety.
Main results: Eighteen randomized placebo-controlled trials were analyzed, i.e., a total of 3244 participants who received opioids and 1612
who received placebo. The mean trial duration was 13 18 weeks. The pooled effect sizes of all opioids vs placebo for pain intensity and
physical function were 0.79 (95% conﬁdence interval, CI, 0.98 to 0.59) and 0.31 (95% CI 0.39 to 0.24), respectively. The NNH
was calculated to be 5 vs placebo. The number of studies (n¼ 4) that compared opioids with non-opioid analgesics (paracetamol and
non-steroidal anti-inﬂammatory drugs) was too limited to provide robust data.
Conclusions: Opioids signiﬁcantly decrease pain intensity and have small beneﬁts on function compared with placebo in patients with OA.
Adverse events, although reversible and not life threatening, often cause participants to stop taking the medication and could limit opioid use-
fulness. Moreover, the long-term efﬁcacy and safety of these drugs for OA is yet to be determined due to the short mean trial duration.
ª 2007 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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SocietyIntroduction
Osteoarthritis (OA) is a chronic degenerative disease asso-
ciated with pain, joint stiffness and joint deformities that may
cause serious disability and interfere with patients’ quality
of life1,2. It is a common condition concerning worldwide
almost 10% of men and 18% of women older than 603, and
the prevalence increases to around 30% for those 70
years old4.
European League Against Rheumatism (EULAR) guide-
lines5,6 state that optimal treatment of knee and hip OA in-
cludes both pharmacological and non-pharmacological
interventions. Among pharmacological agents, ﬁrst line rec-
ommended treatment is oral paracetamol (paracetamol) fol-
lowed by non-steroidal anti-inﬂammatory drugs (NSAIDs).
NSAIDs are an important component of pharmacological
therapy for the management of OA. However, their use is
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2007.9associated with gastrointestinal and renal complications,
especially in elderly patients7,8. Concerns have also
appeared recently regarding the cardio-vascular safety of
selective cyclooxygenase 2 (COX-2) inhibitors and tradi-
tional non-selective NSAIDs9. Furthermore, paracetamol is
often insufﬁcient to treat OA-related pain10. These limita-
tions provide a rationale for exploring the use of opioids to
treat OA-related pain. Moreover, opioid analgesics have
been proposed in OA by EULAR guidelines5,6 in cases of
intense pain and have been recommended by the American
Pain Society as a safe and effective therapeutic option for
the treatment of moderate to severe OA that does not re-
spond to the ﬁrst line treatment11. Nevertheless, their use
(especially in the case of strong opioids) in patients with
pain unrelated to cancer remains controversial12 and is
debated by the United States Senate and European Parlia-
ment13. Thus, it appeared useful to study the effectiveness
and tolerance of opioids in the treatment of OA.
The objectives of this study were to determine the anal-
gesic effectiveness of opioids for osteoarthritic pain, to as-
sess the effectiveness opioids for improving physical
function in patients with OA and to evaluate their safety.
To this end, a meta-analysis of published randomized con-
trolled trials (RCTs) reporting the effects of opioids in OA
was performed.57
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LITERATURE RESEARCH
The objective of the search was to obtain all published
RCTs of opioids in OA. Literature search was performed
on all articles published between 1966 and August 2006
and expanded on Medline, EMBASE and the Cochrane
Controlled Trials Register for RCTs. Papers in English,
French and Spanish languages were eligible for inclusion.
Search was conducted using the following combination:
(‘‘Narcotics’’ [Pharmacological Action] OR ‘‘Analgesics,
Opioid’’ [MeSH]) AND ‘‘Osteoarthritis’’ [MAJR]. In addition,
reference lists of the papers initially detected were hand
searched to identify additional relevant reports.
INCLUSION CRITERIA
Study design
RCTs of opioids vs placebo or non-opioid analgesics.
Comparisons between different opioids were excluded.
Study population
Patients with OA as deﬁned by the authors. In all cases,
the patients fulﬁlled American College of Rheumatology14,15
classiﬁcation criteria for OA and/or were diagnosed by
X-ray. Articles reporting opioid use for post-operative pain
after joint replacement for knee or hip OA were excluded.
Intervention
Any opioid administered via an oral or transdermal route
as a treatment for OA-related pain. For this analysis, opioids
were classiﬁed as weak (codeine, propoxyphene and tra-
madol) or strong (oxycodone, oxytrex, oxymorphone, fen-
tanyl and morphine sulfate).
Outcome measures
Articles were analyzed if an evaluation of pain and/or
functional status and/or safety was available. If an article
reported no interpretable results for all three outcome
measures (pain, function and safety), it was not analyzed.
Efﬁcacy was assessed by the change in overall pain
intensity and/or physical functional status between base-
line and the end of the study, in both active and control
groups.
Pain intensity was extracted from the studies, as
available, by a 100 mm visual analogic scale (VAS), the
WOMAC (Western Ontario and McMaster Universities
Osteoarthritis Index) Index Pain intensity scores or by
a daily four (or ﬁve) point Likert scale. Physical function
was assessed by the WOMAC subscale for physical
function16.
In order to evaluate safety, data were extracted from each
study in both active and control groups regarding the num-
ber of treatment discontinuations due to adverse effects.
Data were also analyzed regarding the number of the fol-
lowing arbitrarily predeﬁned adverse events in both groups:
epigastric pain, nausea, vomiting, constipation, dry mouth,
dizziness, somnolence and headache.
METHODOLOGICAL QUALITY
The articles that fulﬁlled the inclusion criteria underwent
quality appraisal. We used, to assess the quality of RCTs,the impact factor of the journal in which the trial was
published, it was checked whether the statistics used inten-
tion-to-treat analysis and the Jadad scale was applied17,
which contains two questions for randomization and mask-
ing and one question evaluating the reporting of with-
drawals and dropouts. Each question entails a yes or no
response option. In total, 5 points can be awarded, with
higher scores indicating superior quality. Data were also
extracted regarding funding sources for the studies.
DATA EXTRACTION IN INCLUDED STUDIES
Data extraction was performed by one reviewer (J.A.), on
the full texts, not blinded to author and journal, using a pre-
deﬁned extraction sheet, available from the authors. Infor-
mations extracted included ﬁrst author, publication year,
mean age/height/weight/body mass index (BMI) of partici-
pants, sex proportion, trial duration, type of opioid, type of
comparator, drug dose, number of patients in active and
control group, and the outcome measures used to assess
efﬁcacy and safety a priori deﬁned.
STATISTICAL ANALYSIS
To measure the magnitude of the treatment effect for
pain intensity and physical function, the effect size was
calculated. The effect size is a standard way to determine
the degree of improvement (or otherwise) of a particular
therapy after any placebo effect has been accounted for.
The effect size is calculated as the ratio of the treatment
effect (mean differences in treatment group minus differ-
ences in placebo group) to the pooled standard deviation
of these differences18. This calculation entails the use of
means, for both baseline and ﬁnal data (or baseline and
change during study) with a measure of variability such
as standard deviation (SD). Every effort was made to
calculate the effect size in all studies. If the SD was given
in only one group it was used as baseline SD for both
groups. However, if no measure of variability was given
the effect size could not be extrapolated. By convention,
an effect size< 0.2 is usually considered as trivial;
>0.2e0.5 as small; >0.5e0.8 as moderate;> 0.8e1.2 as
important and >1.2 as very important19. Minus or plus
signs indicate direction of difference, not magnitude of
difference.
Primary analyses examined pooled effect size of opioids
vs controls for pain intensity and physical function. Sensitiv-
ity analyses were calculated within subgroups of studies de-
cided a priori (type of opioids, type of scale for pain intensity
and methodological quality) to assess the robustness of the
main conclusions. Quality was analyzed as a binary vari-
able: studies scoring 3 or more on the Jadad scale were
considered to be of high quality; 2 or less, of low quality.
A sensitivity analysis was also performed with the upper
limit for low quality changed to 3.
Statistical heterogeneity was tested by Q test (c2)20. All
meta-analyses were carried out with use of ﬁxed-effects
model, or random-effects model in case of signiﬁcant het-
erogeneity. The number needed to harm (NNH) was used
to assess the safety of opioids. The NNH is an epidemio-
logical measure (deﬁned as the inverse of the absolute
risk increase) which reﬂects the number of patients who, if
they received opioids, would lead to one additional patient
being harmed, compared with control patients. The NNH
is calculated as 1/absolute risk increase, the latter deﬁned
as (experimental event rate-control event rate). Harm was
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because of toxicity and secondarily by the occurrence of
one or more of the a priori deﬁned adverse events. In this
second case, the NNH is the number of patients to treat
to observe the occurrence of one extra adverse event in
the treatment group, compared to the control group. The
advantage of the NNH is that it reﬂects an absolute risk
increase, and because it is related to the control event
rate, it reﬂects the true baseline or underlying risk of the
study population21. For rational decision making in daily
clinical practice, absolute measures such as NNH may be
more meaningful than relative measures22. Because of
the large conﬁdence intervals (CIs) around the opioid
adverse event rates, CIs were not reported for the NNH,
as proposed by McQuay and Moore23.
Results
INCLUDED STUDIES
The results of the article selection process are reported in
Fig. 1. From the 175 articles identiﬁed, 22 (Refs.13,24e44)
were included since they reported RCTs comparing efﬁcacy
and/or safety of opioids vs placebo or non-opioid analgesics
and presented interpretable data. All RCTs were parallel
in design, except one41, which had a cross-over design.
Nine studies concerned strong opioids (oxymorphone,
oxycodone, oxytrex, fentanyl and morphine sulfate) and
13 weak opioids (tramadol, tramadol/paracetamol, codeine
and propoxyphene). All studies were funded by the pharma-
ceutical industry with one exception42. The comparators
were placebo in 18 studies, paracetamol in two studies
and NSAIDs (diclofenac and suprofen) in two studies. In
view of the limited number of studies that evaluated opioids
against other active medications (paracetamol and NSAIDs)
which did not allow us to present robust data, data presented
here concern only the comparison between opioids and
placebo.
QUALITY OF STUDIES
The methodological quality was satisfactory: the mean
SD impact factor of the journals in which were published
the different trials was 3.5 1.5 (range 1.1e7.3) and the
meanSD Jadad score was 3.7 0.6 (range: 2e5). All
but one (95%)31 of these trials used intention-to-treat
analyses.STUDY POPULATION
This systematic review included 4856 OA patients. The
mean age of these patients was 61.6 3 years, 66%
were women and their mean BMI was 33 2 kg/m2. The
characteristics of OA patients are detailed in Table I.
Medline, EMBASE, Cochrane database
and hand search: 
175 publications
Publications excluded on the basis of
the title and abstract 
Not randomized controlled parallel
groups trials: n=63 
Not in English, French or Spanish:
n=15
No osteoarthritis: n=36
No opioids: n=17
Post-operative pain: n=6
Intra-articular opioids: n=6 
Comparison of 2 opioids: n=6
26 studies
Publications excluded after obtaining the
full text 
Data unavailable to calculate the effect
size AND the number needed to harm:
n=3
Full text not available: n=1
22 studies assessed 
Fig. 1. Articles reporting the efﬁcacy and/or the safety of opioids in
osteoarthritis: screening process.Table I
Characteristics of OA patients included in 18 RCTs of opioids compared to placebo
All patients Active intervention group (opioids) Placebo group
Number of patients 4856 3244 1612
Mean age (years)SD (median, range) 61.6 3 (62, 54e70) 61 5 (62, 54e70) 62 3 (62, 54e67)
Female sex, % 66 64 68
Number and % of patients with
Knee OA 2868(59) 1880 (58) 988 (61)
Hip OA 943 (19) 596 (18) 347 (22)
Spine OA 137 (3) 85 (3) 52 (3)
Other localization 40 (1) 25 (1) 15 (1)
Not speciﬁed 868 (18) 658 (20) 210 (13)
Height (cm) meanSD (median, range) 168.6 1.3 (169,165e171) 169.0 1.2 (169, 167e171) 168.0 1.5 (168, 165e169)
Mean weight (kg)SD (median, range) 91.5 6 (94, 74.6e99) 92.6 6 (94, 74.7e99) 89.5 7 (93.5, 74.6e97.3)
Mean BMI (kg/m2)SD (median, range) 33 2 (33, 28e35) 33 2 (33, 28e35) 32 2 (33, 28e35)
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Of the 18 placebo-controlled studies analyzed, 13 pro-
vided the required data on pain intensity for 2438 partici-
pants who received the active treatment and for 1295 who
received placebo. Six studies concerned strong opioids
(oxycodone in four studies, fentanyl and morphine sulfate
in one study) and seven, weak opioids (tramadol in four
studies, tramadol/paracetamol in two studies and codeine
in one study). The mean trial duration was 13 18 weeks
(median 12 weeks, range 1.4e72 weeks).
The effect sizes for pain intensity and physical function
for each of the 13 studies are provided in Tables II and III.
The pooled effect size of all opioids for pain intensity
was 0.79 (95% CI 0.98 to 0.59). The heterogeneity
was substantial (Q¼ 198.5 for 20 degrees of freedom, df;
P< 0.0001). In the assessment of heterogeneity, sensitivity
analyses showed no changes in the conclusions with the
type of opioids, the type of scale used to measure pain in-
tensity (VAS or Likert scale) and methodological quality of
the study (Table IV).
Five placebo-controlled studies evaluated effects of opi-
oids on physical function from 1429 participants receiving
the active treatment (tramadol/paracetamol in two studies,
morphine sulfate, tramadol and codeine in one study each)
and from 595 receiving placebo. The mean trial duration
was 7 5 weeks (median: 4 weeks, range 1.4e13 weeks).
The pooled effect size of all opioids for physical function
was 0.31 (95% CI 0.39 to 0.24). These results were
homogenous (Q¼ 6.8 for 9 df; P¼ 0.66).
SAFETY OF OPIOIDS VS PLACEBO
All the 18 studies provided suitable data to assess opioid
safety. The most frequent adverse events reported with opi-
oids were nausea (30%), constipation (23%), dizziness
(20%), somnolence (18%) and vomiting (13%).
The average treatment discontinuation rate for toxicity
was 25% (818/3244) in the opioid group (516/1650, 31%
for strong opioids and 302/1594, 19% for weak opioids)
and 7% (116/1612) in the placebo group. Thus, the NNH
for all class of opioids vs placebo was 5; for strong and
weak opioids it was 4 and 9, respectively.
The NNHs vs placebo calculated for each adverse event
(a priori deﬁned) are provided in Table V.
Discussion
This meta-analysis suggests that in OA opioids are more
effective than placebo to reduce pain intensity and improve
physical function. These results are consistent with pub-
lished data8,45. However, the beneﬁts on physical function
are small (effect size< 0.5), and may not be clinically rele-
vant. This may be explained by the mechanism of action of
opioids (they do not have anti- inﬂammatory effects)30 and
the short follow-up periods, as three trials out of ﬁve analyz-
ing effects on physical function were short (from 1.4 to 4
weeks) to estimate the efﬁcacy of opioids on func-
tion34,35,37. Moreover, opioids may also inﬂuence the effects
on physical function because of side effects such as diz-
zines and drowsiness.
Opioid beneﬁts may be limited by the occurrence of ad-
verse events. The NNH of all class of opioids vs placebo
for major adverse events indicates that, of every ﬁve pa-
tients who received opioid therapy, one discontinued the
medication because of the occurrence of an adverse event.This was particularly important for strong opioids with an
NNH of 4, vs 9 for weak opioids. Moreover, ﬁve of the a priori
deﬁned side effects (nausea, somnolence, dizziness, vom-
iting and constipation) were very frequent, with NNHs rang-
ing from 4 to 9. These data emphasize the fact that adverse
events need to be considered when treating OA patients
with opioids.
This meta-analysis did not permit us to assess how opi-
oids compare with other available pharmacological treat-
ments (paracetamol and NSAIDs) because of the limited
number of studies. Additional efﬁcacy and safety monitoring
investigations are needed.
This analysis had some limitations that merit consider-
ations. Because of the absence of subgroup analyses in
the articles reviewed, it was not possible to conduct sub-
group analysis using meta-regressions to assess potential
effect modiﬁcation by type of patient (sex, age, BMI), dis-
ease duration or trial duration. Thus, we were limited in
our ability to fully and clearly assess heterogeneity in opi-
oids analgesic effectiveness.
Chronic pain is a long-term disorder. The studies included
in this meta-analysis had various follow-up periods; most tri-
als were not long enough to estimate the efﬁcacy of opioids
in chronic pain, the potential for opioid tolerance, or long-
range adverse effects.
Another limitation of these results is the handling of miss-
ing data: one of the studies did not perform intention-to-treat
analysis31, while others performed intention-to-treat analysis
with the last-value-carried-forward method32,37. Serious
ﬂaws still prevailed as all randomized patients were not
included in the intention-to-treat analysis in one of these
trials30, and the best case scenario used for intention-
to-treat analysis limits the validity of results, even if the
quality of study was generally satisfactory.
Potential publication bias introduced into the process of
locating and selecting studies for inclusion cannot be ex-
cluded because studies with signiﬁcant results are more
likely to be published than studies without signiﬁcant
results46.
With the exception of one study, all the rest were in-
dustry funded and there is evidence suggesting that in-
dustry funded studies could overestimate treatment
effects47.
This systematic review emphasized some implications
for practice and future research. The evaluation of the
long-term effectiveness/safety of opioids for the treatment
of OA is important: these agents are increasingly used to
treat OA despite a lack of strong supporting evidence for
their long-term effectiveness, and despite concerns about
their tolerability and long-term safety. However, published
data are relatively scarce for such a frequent disease. In
particular, well designed equivalence RCTs that compare
head to head the effectiveness and safety proﬁles of
opioids and paracetamol or NSAIDs are warranted, in or-
der to guide clinicians in selecting the best treatment
approach.
Furthermore, additional trials are desirable in OA for
other-than-oral routes of administration; for example, we
found only one randomized placebo-controlled trial of trans-
dermal route.
Finally, these results suggest that, when compared to
placebo, opioids are superior for improving pain (with an
advantage for strong opioids) and have small beneﬁts
on physical function in OA patients.
The number of studies (n¼ 4) that compared opioids with
non-opioid analgesics (paracetamol and NSAIDs) was too
limited to provide robust data.
nd physical function in patients with OA
Author, Reference ts,
bo
Outcome measure Effect size (95% CI)
Langford13 Pain intensity VAS (0e100 mm) 0.37 (0.57 to 0.17)
Chindalore26 Pain intensity VAS (0e100 mm) 1.09 (1.45 to 0.73)
0.29 (0.63 to þ0.05)
0.15 (0.49 to þ0.18)
Markenson28 Pain intensity VAS (0e100 mm) 1.49 (1.92 to 1.05)
Zautra29 Pain intensity VAS (0e100 mm) 0.75 (1.15 to 0.34)
Cadwell34 Pain intensity VAS (0e100 mm) 0.74 (1.07 to 0.40)
0.55 (0.89 to 0.22)
0.57 (0.90 to 0.24)
WOMAC physical function 0.34 (0.67 to 0.01)
0.33 (0.66 to 0.03)
0.25 (0.58 to þ0.07)
Roth38 Four point scale for pain intensity 1.98 (2.50 to 1.46)
4.96 (5.82 to 4.09)
Kinitz24 Pain intensity VAS (0e100 mm) Insufﬁcient data to calculate
the effect size
Matsumoto27 Pain intensity VAS (0e100 mm) Insufﬁcient data to calculate
the effect size
Cadwell39 Four point scale for pain intensity Insufﬁcient data to calculate
the effect size
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Characteristics of controlled trials comparing strong opioids with placebo for pain intensity a
Jadad score Opioid Dose Trial duration
(weeks)
Number of patien
intervention/place
4 Fentanyl TD 25e100 mg/h 6 202/197
4 Oxytrex bid 10e40 mg/day 3 310/52
Oxytrex qid 10e40 mg/day
Oxycodone 10e40 mg/day
4 Oxycodone CR 10 mg/day 13 56/51
4 Oxycodone CR 10e120 mg/day 13 55/49
4 Morphine sulfate QAM 30 mg/day 4 222/73
Morphine sulfate QPM 30 mg/day
Morphine sulfate CR 30 mg/day
3 Oxycodone 10 mg 20 mg/day 2 88/45
Oxycodone 20 mg 40 mg/day
4 Oxymorphone ER 20 mg/day 2 279/91
40 then 80 mg/day
40 then 100 mg/day
4 Oxycodone ER 20 mg/day 4 367/124
Oxycodone ER 40 mg/day
Oxycodone CR 40 mg/day
4 Oxycodone 20e60 mg/day 4 71/36
Oxycodone/paracetamol 5/325e60/4000 mg/day
ase, ER: extended release, QAM: once daily in the morning, QPM: once daily in the evening, bid: t
hysical function in patients with OA
Author, Reference Jada ts
o
Outcome measure Effect size (95% CI)
Gana25 Pain intensity VAS (0e100 mm) 0.37 (0.57 to 0.17)
0.48 (0.68 to 0.28)
0.50 (0.70 to 0.30)
0.37 (0.57 to 0.17)
WOMAC Physical function 0.29 (0.48 to 0.09)
0.36 (0.56 to 0.16)
0.30 (0.50 to 0.10)
0.28 (0.48 to 0.09)
Emkey30 Pain intensity VAS (0e100 mm) 0.49 (0.72 to 0.26)
WOMAC Physical function 0.20 (0.42 to þ0.03)
Malonne31 Pain intensity VAS (0e100 mm) 0.58 (0.85 to 0.32)
Babul32 Pain intensity VAS (0e100 mm) 0.93 (1.19 to 0.66)
Silverﬁeld35 Four point scale for pain intensity 0.60 (0.83 to 0.36)
WOMAC Physical function 0.31 (0.54 to 0.07)
Fleischmann36 Five point scale for pain intensity 0.36 (0.7 1to 0.01)
Peloso37 Pain intensity VAS (0e100 mm) 1.22 (1.65 to 0.79)
WOMAC Physical function 0.78 (1.19 to 0.37)
Rozenthal33 Four point scale for pain intensity Insufﬁcient data
to calculate the effect size
Roth40 Time to exit study because of
therapeutic failure
Insufﬁcient data o calculate
the effect size
CR: controlled releas a day, qid: four times a day.
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Characteristics of controlled trials comparing weak opioids with placebo for pain intensity and p
d score Opioid Dose Trial duration (weeks) Number of patien
intervention/placeb
4 Tramadol ER 100 mg/day 12 806/205
200 mg/day
300 mg/day
400 mg/day
3 Tramadol/paracetamol 37.7/325e300/2600 mg/day 13 153/154
3 Tramadol ER 200 mg/day 2 111/119
4 Tramadol ER 100e400 mg/day 12 124/122
5 Tramadol/paracetamol 37.5/325e300/2600 mg/day 1.4 197/111
3 Tramadol 50e400 mg/day 13 63/66
4 Codeine 100 mg/day 4 51/52
4 Tramadol/paracetamol 168/1500 mg/day 1.5 69/44
2 Tramadol 50e400 mg 2 20/21
e, ER: extended release, QAM: once daily in the morning, QPM: once daily in the evening, bid: twice
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Sensitivity analyses of opioids vs placebo for pain intensity
Characteristics No of studies Fixed-effects model Random-effects model Q (P value)
Effect size 95% CI Effect size 95% CI
All studies 13 0.58 0.64 to 0.52 0.79 0.98 to 0.59 198.5 (P< 0.0001)
Type of opioids
Strong 6 0.69 0.79 to 0.60 1.08 1.52 to 0.65 165.8 (P< 0.0001)
Weak 7 0.52 0.60 to 0.45 0.56 0.69 to 0.43 26.1 (P< 0.002)
Oxycodone 4 0.93 1.08 to 0.78 1.46 144.8 (P< 0.0001)
Fentanyl 1 0.37 0.57 to 0.17 NA
Morphine sulfate 1 0.62 0.81 to 0.43 2.23 to 0.69 0.70 (P¼ 0.7)
Tramadol and
tramadol/paracetamol
6 0.50 0.58 to 0.43 0.51 15.3 (P¼ 0.053)
Codeine 1 1.22 1.65 to 0.79 0.62 to 0.41 NA
Type of scale
VAS 9 0.53 0.59 to 0.46 0.58 0.70 to 0.45 55.4 (P< 0.0001)
Likert score 4 0.79 0.96 to 0.62 1.01 1.61 to 0.41 33.2 (P< 0.0001)
High methodological
quality (cut-off 3)
High quality (4 and 5) 9 0.53 0.60 to 0.47 0.59 0.72 to 0.46 57.5 (P< 0.0001)
Low quality (1, 2 and 3) 4 0.62 0.77 to 0.47 0.81 1.31 to 0.31 30.7 (P< 0.0001)Adverse events, although reversible and not life threaten-
ing, often caused participants to stop taking the medication
and could limit opioids usefulness.
Future trials of opioids for OA compared with non-
opioid analgesics are warranted. They should consistentlyhave well-deﬁned methods and follow-up periods ade-
quate in length. More attention should be paid to factors
affecting methodological rigor, such as success of blind-
ing, avoidance of dropouts, and adequate intention-
to-treat analysis.Table V
NNH calculation for adverse events reported for opioids vs placebo
Adverse event (AE) Opioids No (%) of AE in OA patients
treated with opioids in
studies where the AE was reported
No (%) of AE in OA patients
treated with placebo in studies
where the AE was reported
NNH
Epigastric pain All class 19/698 (3) 5/447 (1) 50
Weak 4/388 (1) 3/395 (0.8) 500
Strong 15/310 (5) 2/52 (4) 50
Nausea All class 950/3138 (30) 145/1511 (9.5) 5
Weak 315/1543 (20) 49/842 (6) 7
Strong 635/1595 (40) 96/669 (14) 4
Vomiting All class 408/3075 (13) 32/1445 (2) 9
Weak 118/1480 (8) 15/776 (2) 17
Strong 290/1595 (18) 17/669 (2) 6
Constipation All class 733/3189 (23) 88/1563 (5.6) 4
Weak 275/1594 (17) 36/894 (4) 8
Strong 458/1595 (29) 52/669 (8) 5
Dry mouth All class 213/2532 (8) 19/1041 (2) 17
Weak 69/1214 (6) 5/621 (1) 22
Strong 144/1318 (11) 14/420 (3) 12
Dizziness All class 633/3189 (20) 83/1563 (5) 7
Weak 278/1594 (17) 45/894 (5) 8
Strong 355/1595 (22) 38669 (6) 6
Somnolence All class 549/3126 (18) 55/1497 (4) 8
Weak 166/1531 (11) 16/828 (2) 11
Strong 383/1595 (24) 39/669 (6) 6
Headache All class 343/2649 (13) 128/1255 (10) 33
Weak 145/1155 (12.5) 52/653 (8) 22
Strong 198/1494 (13) 76/602 (13) Inﬁnite
NNH for overall adverse events 5
Discontinuation rate for adverse events (opioids/placebo) 25% / 7%
No: number, AE: adverse event, OA: osteoarthritis, NNH: calculation of the number of patients which need to be treated by opioids to
observe one supplementary treatment discontinuation due to an AE in the opioid arm, compared to the placebo arm.
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